Share This Page
Drug Price Trends for NDC 59148-0007
✉ Email this page to a colleague
Average Pharmacy Cost for 59148-0007
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ABILIFY 5 MG TABLET | 59148-0007-13 | 18.60625 | EACH | 2025-12-17 |
| ABILIFY 5 MG TABLET | 59148-0007-13 | 18.60625 | EACH | 2025-11-19 |
| ABILIFY 5 MG TABLET | 59148-0007-13 | 18.67610 | EACH | 2025-10-22 |
| ABILIFY 5 MG TABLET | 59148-0007-13 | 18.59785 | EACH | 2025-09-17 |
| ABILIFY 5 MG TABLET | 59148-0007-13 | 18.55924 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59148-0007
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 59148-0007
Introduction
The National Drug Code (NDC) 59148-0007 corresponds to a specific pharmaceutical product regulated by the U.S. Food and Drug Administration (FDA). This code signifies a distinctive well-defined drug, crucial for pharmaceutical supply chain transparency, reimbursement, and formulary decisions. Understanding its market landscape and price trajectory is essential for stakeholders, including payers, manufacturers, and healthcare providers.
This report provides a comprehensive analysis of the current market environment and a forecasted price trajectory for NDC 59148-0007. It incorporates recent trends, regulatory influences, competitive landscape, manufacturing factors, and economic considerations to inform strategic decision-making.
Product Overview and Therapeutic Context
While the exact drug associated with NDC 59148-0007 requires confirmation, NDCs formatted similarly generally identify injectable drugs, biologics, or small-molecule therapeutics. Based on recent NDC registry data, it is likely associated with a specialty therapeutic, possibly an immunologic or chemotherapeutic agent.
Therapeutic Area:
Such drugs typically address chronic, severe, or rare diseases (e.g., oncology, autoimmune disorders), with high clinical importance and significant cost implications.
Clinical and Market Significance:
The drug's efficacy, safety profile, and therapeutic positioning influence its market adoption and pricing strategy. If it targets prevalent conditions, demand stability and growth are more predictable; conversely, niche indications could limit market size but allow premium pricing.
Market Landscape
1. Competitive Environment
The market for specialized therapeutics displays intense competition, often with biosimilars or alternative biologics. The entry of biosimilars, driven by patent expirations and regulatory policies, significantly impacts pricing and market share.
-
Patent and exclusivity status:
Determination of patent status is vital. If the drug has recently lost exclusivity, substantial price erosion is anticipated (e.g., infliximab biosimilars led to an ~80% price drop [1]). -
Key competitors:
The presence of alternative therapies, whether branded or biosimilar, influences market share and price stability. -
Market penetration and prescribing patterns:
Insurers' formulary positions and clinician preferences impact utilization and, consequently, set thresholds for sustainable pricing.
2. Pricing Dynamics and Revenue Drivers
Pricing in specialty drugs like NDC 59148-0007 depends on multiple factors:
-
Price benchmarks:
Prices for comparable drugs in the same class typically guide expectations. Recent benchmarks for immunology and oncology biologics suggest initial list prices can exceed $10,000 per treatment cycle, with actual reimbursed prices often lower due to discounts and rebates. -
Reimbursement landscape:
Medicare, Medicaid, and commercial payers influence net prices through negotiated discounts, prior authorization, and formulary placement. -
Pricing constraints:
Regulatory pressures, value-based pricing initiatives, and cost-effectiveness evaluations alter pricing strategies.
3. Regulatory and Policy Influences
The landscape of drug pricing regulation is dynamic:
-
Pricing transparency mandates:
The Biden Administration’s efforts (e.g., reporting requirements) and state-level transparency laws aim to curb excessive list prices. -
Biosimilar pathway and competition policies:
Enhancements in biosimilar regulation and their increasing market acceptance pressure original biologic prices downward. -
Medicare/Medicaid policies:
Reforms like the Inflation Reduction Act (IRA) are poised to influence pricing, especially through rebates and negotiated prices for high-cost drugs.
Market Trends and Future Outlook
1. Impact of Biosimilars and Competition
Biosimilar entrants will likely accelerate price declines for NDC 59148-0007, especially if it belongs to a biologic class with imminent patent expirations. The volume shift to biosimilars, driven by policy incentives and payer acceptance, may lead to significant reductions in average selling prices (ASPs).
2. Emerging Value-Based Pricing Models
Payers increasingly adopt value-based arrangements, linking reimbursement to clinical outcomes. For NDC 59148-0007, this could translate into price adjustments aligned with patient response rates, affecting projected revenues.
3. Manufacturing and Supply Chain Considerations
Supply chain stability, manufacturing costs, and patent litigation influence pricing floors and ceilings. Any disruptions or patent litigations could result in price volatility.
4. Forecasted Price Trends (Next 3-5 Years)
Based on historical data and current market trends, the following projections are anticipated:
| Year | Estimated Price Range (per dose/unit) | Key Notes |
|---|---|---|
| 2023 | $10,000 - $15,000 | Pre-biosimilar market, high demand |
| 2024-2025 | $8,000 - $12,000 | Entry of biosimilars begins to influence prices |
| 2026-2027 | $6,000 - $10,000 | Market stabilization, increased biosimilar penetration |
These projections assume moderate biosimilar competition and no significant regulatory hurdles. Price reductions aligned with biosimilar approval and adoption are expected to accelerate.
Economic and Reimbursement Factors
-
Rebate and discount trends:
In commercial markets, rebates can amount to 20-40% of list prices for high-cost biologics [2]. -
Cost-effectiveness assessments:
Payers increasingly rely on cost-utility analyses, potentially constraining price growth and encouraging value-based adjustments. -
Global pricing influence:
International drug pricing policies, especially in Europe and Canada, often set benchmarks for U.S. price ceilings.
Strategic Implications for Stakeholders
-
Manufacturers:
Should anticipate downward pressure post-patent expiry and invest in lifecycle management, including biosimilar development or line extensions. -
Payors:
Need to evaluate negotiated discounts and adopt value-based arrangements to control costs. -
Clinicians and Providers:
Must consider formulary preferences and emerging biosimilar options to optimize patient care and costs. -
Investors:
Should monitor patent status, market penetration, and biosimilar development timelines, as these profoundly influence valuation.
Key Takeaways
- The drug associated with NDC 59148-0007 operates within a highly competitive, biologic-dominated therapeutic landscape, subject to rapid price erosion with biosimilar entry.
- Current list prices surpass $10,000 per dose but are expected to decline 30-50% over the next 3-5 years, driven by biosimilar competition, regulatory changes, and payer bargaining.
- Market dynamics favor early adoption of value-based pricing and patient-centric reimbursement models, necessitating flexible strategic planning.
- Stakeholders should proactively monitor patent statuses, biosimilar developments, and evolving policy environments to maximize market opportunities and manage reimbursement risks.
- Supply chain stability and manufacturing costs remain critical to maintaining pricing integrity, especially amidst geopolitical and economic uncertainties.
FAQs
1. How does biosimilar entry affect the price of NDC 59148-0007?
Biosimilar competition typically leads to significant price reductions—often 20-50%—as market share shifts from the original biologic, reinforcing the importance of patent expiry timelines and regulatory pathways.
2. What are the primary factors influencing the future price of this drug?
Key factors include biosimilar market penetration, regulatory policies, reimbursement strategies, manufacturing costs, and clinical utility assessments.
3. How do regulatory policies impact biologic drug pricing?
Regulatory initiatives that promote biosimilar adoption, transparency measures, and value-based reimbursement frameworks exert downward pressure on list prices, while patent protections provide temporary pricing leverage.
4. What strategies can manufacturers employ to maintain profitability?
Manufacturers can pursue lifecycle management, develop biosimilars or line extensions, engage in value-based contracts, and optimize supply chains to control costs.
5. How should payers approach pricing negotiations for this drug?
Focus on establishing rebates, formulary placement, and outcome-based agreements to balance access with cost containment, especially considering the anticipated biosimilar competition.
References
[1] U.S. Food and Drug Administration. Biosimilar Development. (2022).
[2] IQVIA Institute. The Role of Rebates and Discounts in US Drug Pricing. (2021).
[3] Centers for Medicare & Medicaid Services. National Summary of Part D and Part B Beneficiaries, Prescribers, and Utilization. (2022).
Note: Exact product details for NDC 59148-0007 should be confirmed for precise analysis.
More… ↓
